Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 12
1993 1
1996 1
1998 1
2009 1
2014 1
2017 3
2018 7
2019 8
2020 3
2021 5
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate.
Yawalkar S, Wiesenberg-Boettcher I, Gibson JR, Siskin SB, Pignat W. Yawalkar S, et al. J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1137-44. doi: 10.1016/0190-9622(91)70312-p. J Am Acad Dermatol. 1991. PMID: 1757603 Review.
There was a trend in favor of halobetasol propionate in the cutaneous vasoconstriction assay performed in volunteers with ethanol solutions of halobetasol propionate and clobetasol 17-propionate. In a further vasoconstriction assay, performed with a 0.05% concentrat …
There was a trend in favor of halobetasol propionate in the cutaneous vasoconstriction assay performed in volunteers with ethanol sol …
A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
Kerdel FA, Draelos ZD, Tyring SK, Lin T, Pillai R. Kerdel FA, et al. J Dermatolog Treat. 2019 Jun;30(4):333-339. doi: 10.1080/09546634.2018.1523362. Epub 2018 Nov 5. J Dermatolog Treat. 2019. PMID: 30207807 Clinical Trial.
Background: Halobetasol propionate (HP) 0.05% is a highly effective short-term treatment for plaque psoriasis. ...There was one treatment-related application-site reaction with HP 0.01% lotion, and no AE reports of skin atrophy, striae, telangiectasia, or folliculitis. Con …
Background: Halobetasol propionate (HP) 0.05% is a highly effective short-term treatment for plaque psoriasis. ...There was one treat …
Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
Stein Gold L, Bagel J, Lebwohl M, Lin T, Martin G, Pillai R. Stein Gold L, et al. J Drugs Dermatol. 2018 Dec 1;17(12):1290-1296. J Drugs Dermatol. 2018. PMID: 30586261 Clinical Trial.
Background: A unique fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion has been shown to be effective in psoriasis using Investigator Global Assessment (IGA) tools to assess erythema, plaque elevation, and scaling. ...Objective: To furthe …
Background: A unique fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion has been shown to be effect …
A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL, Gold LS, Lebwohl MG, Pariser DM, Alexander BJ, Pillai R. Sugarman JL, et al. J Drugs Dermatol. 2017 Mar 1;16(3):197-204. J Drugs Dermatol. 2017. PMID: 28301614 Clinical Trial.
OBJECTIVE: To investigate the efficacy and safety of a once-daily application of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion in comparison with its monads and vehicle in subjects with moderate-to-severe plaque psoriasis. ...Safety …
OBJECTIVE: To investigate the efficacy and safety of a once-daily application of a fixed combination halobetasol propionate 0.01% and …
Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
Green LJ, Kerdel FA, Cook-Bolden FE, Bagel J, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T. Green LJ, et al. J Drugs Dermatol. 2018 Oct 1;17(10):1062-1069. J Drugs Dermatol. 2018. PMID: 30365586 Clinical Trial.
Safety and treatment emergent adverse events (AEs) evaluated throughout. RESULTS: Halobetasol propionate 0.01% lotion demonstrated statistically significant superiority over vehicle as early as week 2. ...Halobetasol propionate 0.01% lotion was well-tolerated with n …
Safety and treatment emergent adverse events (AEs) evaluated throughout. RESULTS: Halobetasol propionate 0.01% lotion demonstrated st …
Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Patients With Skin of Color.
Alexis AF, Desai SR, Han G, Jacobson A. Alexis AF, et al. J Drugs Dermatol. 2021 Jul 1;20(7):744. doi: 10.36849/JDD.735. J Drugs Dermatol. 2021. PMID: 34232005 Clinical Trial.
BACKGROUND: Few studies have examined topical psoriasis therapies in patients with skin of color. Fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) was investigated in two phase 3, multicenter, double-blind, vehicle-controlled trials …
BACKGROUND: Few studies have examined topical psoriasis therapies in patients with skin of color. Fixed-combination halobetasol propi …
Halobetasol Propionate Lotion, 0.05% Provides Superior Hydration Compared to Halobetasol Propionate Cream, 0.05% in a Double-Blinded Study of Occlusivity and Hydration.
Grove G, Zerweck C, Houser T, Andrasfay A, Gauthier B, Holland C, Piacquadio D. Grove G, et al. J Drugs Dermatol. 2017 Feb 1;16(2):140-144. J Drugs Dermatol. 2017. PMID: 28300856 Clinical Trial.
BACKGROUND: This study measured skin hydration and occlusivity of two test products [halobetasol propionate lotion, 0.05% (HBP Lotion) and Ultravate (halobetasol propionate) cream, 0.05% (HBP Cream)] at 2, 4, and 6 hours after application to skin test sites previous …
BACKGROUND: This study measured skin hydration and occlusivity of two test products [halobetasol propionate lotion, 0.05% (HBP Lotion …
Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants.
Desai SR, Glick B, Del Rosso JQ, Harris S, Jacobson A. Desai SR, et al. J Drugs Dermatol. 2021 Mar 1;20(3):252-258. doi: 10.36849/JDD.5698. J Drugs Dermatol. 2021. PMID: 33683083 Clinical Trial.
BACKGROUND: Psoriasis is a chronic, inflammatory disease that may differ in prevalence and clinical presentation among patients from various racial and ethnic groups. Two phase 3 studies demonstrated efficacy and safety of halobetasol propionate (HP) 0.01% lotion in the tr …
BACKGROUND: Psoriasis is a chronic, inflammatory disease that may differ in prevalence and clinical presentation among patients from various …
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T. Gold LS, et al. J Am Acad Dermatol. 2018 Aug;79(2):287-293. doi: 10.1016/j.jaad.2018.03.040. Epub 2018 Apr 1. J Am Acad Dermatol. 2018. PMID: 29614243 Free article. Clinical Trial.
Combining them with tazarotene may optimize their efficacy and minimize safety and tolerability concerns. OBJECTIVE: To investigate the safety and efficacy of halobetasol propionate 0.01% plus tazarotene 0.045% (HP/TAZ) lotion in moderate-to-severe plaque psoriasis. ...
Combining them with tazarotene may optimize their efficacy and minimize safety and tolerability concerns. OBJECTIVE: To investigate the safe …
Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
Tanghetti EA, Bhatia N, Drew S, Jacobson A. Tanghetti EA, et al. J Drugs Dermatol. 2021 Aug 1;20(8):829-836. doi: 10.36849/JDD.6217. J Drugs Dermatol. 2021. PMID: 34397206 Clinical Trial.
INTRODUCTION: Patients with psoriasis and low body surface area (BSA) involvement often experience substantially reduced quality of life and may be candidates for topical therapies. Fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/TAZ) vs …
INTRODUCTION: Patients with psoriasis and low body surface area (BSA) involvement often experience substantially reduced quality of life and …
42 results